Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 3/20 | 0.40 |
| ▸ | STS | P08842 | 2/20 | 0.39 |
| ▸ | MCL1 | Q07820 | 4/20 | 0.39 |
| ▸ | BCL2 | P10415 | 1/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.38 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.37 |
| ▸ | GHSR | Q92847 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1013790 | 1.00 | TACR1 (0.40) | TACR1STSMCL1BCL2PDE4B | |
| SCHEMBL14278109 | 1.00 | TACR1 (0.40) | TACR1STSMCL1BCL2PDE4B | |
| SCHEMBL14278205 | 0.88 | ADAM17 (0.37) | MCL1ADAM17 | |
| SCHEMBL14278161 | 0.87 | ADAM17 (0.35) | MCL1ADAM17GHSR | |
| SCHEMBL14278204 | 0.87 | — | — | |
| SCHEMBL14278206 | 0.86 | CCR1 (0.41) | — | |
| SCHEMBL14278078 | 0.86 | MCL1 (0.37) | STSMCL1ADAM17 | |
| SCHEMBL14278217 | 0.86 | MCL1 (0.37) | STSMCL1ADAM17 | |
| SCHEMBL1013961 | 0.85 | STS (0.46) | STSMCL1ADAM17 | |
| SCHEMBL1070360 | 0.85 | STS (0.46) | STSMCL1ADAM17 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2272858-A2 | HCV inhibitors comprising beta amino acids and their uses | Novartis AG (CH) | 2011-01-12 | — | — | EP | disclosed |
| US-20080045530-A1 | Organic Compounds and Their Uses | BRANDL TRIXI | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045530-A1 | Organic Compounds and Their Uses | OAT, OTC, AOX1 | TACR1 2139/4885STS 1434/4885MCL1 1531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.